Hypertrophic Cardiomyopathy

  • Paul Sorajja
  • Steve R. Ommen


A 22-year-old male college student who has been previously healthy presents with new symptoms of dyspnea. As a child and young adult, he had been told of a physiologic murmur but was never diagnosed with a heart condition.


Mitral Regurgitation Coronary Flow Reserve Left Ventricular Outflow Tract Myocardial Hypertrophy Left Ventricular Outflow Tract Obstruction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Maron BJ, Shirani J, Poliac LC, et al. Sudden death in young competitive athletes: clinical, demographic and pathological profiles. JAMA 1996;276;199–204.PubMedCrossRefGoogle Scholar
  2. 2.
    Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation 1995;92:785–789.PubMedCrossRefGoogle Scholar
  3. 3.
    McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda M. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 1997;77:130–132.PubMedGoogle Scholar
  4. 4.
    Maron BJ, McKenna WJ, Danielson GK, et al., Task Force on Clinical Expert Consensus Documents, American College of Cardiology, Committee for Practice Guidelines, European Society of Cardiology, American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003;42:1687–1713.PubMedCrossRefGoogle Scholar
  5. 5.
    Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med 1998;339:364–369.PubMedCrossRefGoogle Scholar
  6. 6.
    Corrado D, Pelliccia, A, Bjornstad HH, et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005;26:516–524.PubMedCrossRefGoogle Scholar
  7. 7.
    IOC Medical Commission, International Olympic Committee. Sudden Cardiovascular Death in Sport: Lausanne Recommendations: Preparticipation Cardiovascular Screening. December 10, 2004. Available at Accessed January 23, 2008.
  8. 8.
    Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Circulation 2007;115:1643–455.PubMedCrossRefGoogle Scholar
  9. 9.
    Pelliccia A, Di Paolo FM, Corrado D, et al. Evidence for efficacy of the Italian national pre-participation screening programme for identification of hypertrophic cardiomyopathy in competitive athletes. Eur Heart J 2006;27:2196–2200.PubMedCrossRefGoogle Scholar
  10. 10.
    Colucci M. Part I: organization of sport (Italy), §2,IV (Sports Doctors). In: Hendrickx F (ed) International Encyclopaedia of Laws: Sports Law. New York, NY: Aspen Publishers; 2004;29–31.Google Scholar
  11. 11.
    Prescott E. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Eur Heart J 2006;27:2904–2905.PubMedCrossRefGoogle Scholar
  12. 12.
    Hanson JR. Screening is inefficient and too expensive for the NHS. BMJ 2008;337:a906.PubMedCrossRefGoogle Scholar
  13. 13.
    Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes: insights into methods for distinguishing athlete’s heart from structural heart disease with particular emphasis on hypertrophic cardiomyopathy. Circulation 1995;91:1596–1601.PubMedCrossRefGoogle Scholar
  14. 14.
    Sharma S, Maron BJ, Whyte G, et al. Physiologic limits of left ventricular hypertrophy in elite junior athletes: relevance to differential diagnosis of athlete’s heart and hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;40:1431–1436.PubMedCrossRefGoogle Scholar
  15. 15.
    Pelliccia A, Maron BJ, De Luca R, et al. Remodeling of left ventricular hypertrophy in elite athletes after long-term deconditioning. Circulation 2002;105:944–949.PubMedCrossRefGoogle Scholar
  16. 16.
    Basavarajaiah S, Wilson M, Junagde S, et al. Physiological left ventricular hypertrophy or hypertrophic cardiomyopathy in an elite adolescent athlete: role of detraining in resolving the clinical dilemma. Br J Sports Med 2006;40:727–729.PubMedCrossRefGoogle Scholar
  17. 17.
    Sharma S, Elliott PM, Whyte G, et al. Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol 2000;36:864–870.PubMedCrossRefGoogle Scholar
  18. 18.
    Radvan J, Choudhury L, Sheridan DJ, Camici PG. Comparison of coronary vasodilator reserve in elite rowing athletes versus hypertrophic cardiomyopathy. Am J Cardiol 1997;80:1621–1623.PubMedCrossRefGoogle Scholar
  19. 19.
    Vinereanu D, Florescu N, Sculthorpe N, et al. Differentiation between pathologic and physiologic left ventricular hypertrophy by tissue Doppler assessment of long-axis function in patients with hypertrophic cardiomyopathy or systemic hypertension and in athletes. Am J Cardiol 2001;88:53–58.PubMedCrossRefGoogle Scholar
  20. 20.
    Cardim N, Oliveira AG, Longo S, et al. Doppler tissue imaging: regional myocardial function in hypertrophic cardiomyopathy and in athlete’s heart. J Am Soc Echocardiogr 2003;16:223–232.PubMedCrossRefGoogle Scholar
  21. 21.
    Saghir M, Areces M, Makan M. Strain rate imaging differentiates hypertensive cardiac hypertrophy from physiologic cardiac hypertrophy. J Am Soc Echocardiogr 2007;20:151–157.PubMedCrossRefGoogle Scholar
  22. 22.
    Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchio C. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 1989;320:749–755.PubMedCrossRefGoogle Scholar
  23. 23.
    Montgomery JV, Harris KM, Casey SA, Zenovich AG, Maron BJ. Relation of electrocardiographic patterns to phenotypic expression and clinical outcome in hypertrophic cardiomyopathy. Am J Cardiol 2005;96:270–275.PubMedCrossRefGoogle Scholar
  24. 24.
    Hansen MW, Merchant N. MRI of hypertrophic cardiomyopathy: part I, MRI appearances. Am J Roentgenol 2007;189:1335–1343.CrossRefGoogle Scholar
  25. 25.
    Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, Weil J, Zenovich AG, Maron BJ. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005;112:855–861.PubMedCrossRefGoogle Scholar
  26. 26.
    Moon JC, Reed E, Shephard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;43:2260–2264.PubMedCrossRefGoogle Scholar
  27. 27.
    Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;40:2156–2164.PubMedCrossRefGoogle Scholar
  28. 28.
    Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51:1369–1374.PubMedCrossRefGoogle Scholar
  29. 29.
    Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365–373.PubMedCrossRefGoogle Scholar
  30. 30.
    Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212–2218.PubMedCrossRefGoogle Scholar
  31. 31.
    Maron BJ, Ackerman MJ, Nishimura RA, Pyeritz RE, Towbin JA, Udelson JA. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol 2005;45:1340–1345.PubMedCrossRefGoogle Scholar
  32. 32.
    Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004;109:2807–2816.PubMedCrossRefGoogle Scholar
  33. 33.
    Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104:2517–2524.PubMedCrossRefGoogle Scholar
  34. 34.
    Maron BJ, Olivotto I, Bellone P, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:301–307.PubMedCrossRefGoogle Scholar
  35. 35.
    Sorajja P, Ommen SR, Nishimura RA, et al. Adverse prognosis of patients with hypertrophic cardiomyopathy and epicardial coronary artery disease. Circulation 2003;108:2342–2348.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Mayo Clinic College of MedicineMayo ClinicRochesterUSA

Personalised recommendations